Showing 71-80 of 7163 results for "".
American Academy of Dermatology Conference Takeaways: M&A and the Economy
https://practicaldermatology.com/conferences/aad-2023/american-academy-of-dermatology-conference-takeaways-mampa-and-the-economy/23906/Highlights from the 2023 American Academy of Dermatology annual meeting and survey of strategic buyers.An Inside Look at How Incyte is Addressing Unmet Needs of Patients with Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/an-inside-look-at-how-incyte-is-addressing-unmet-needs-of-patients-with-atopic-dermatitis/20156/Ahmad Naim, Vice President of US Medical Affairs at Incyte, discusses the challenges around atopic dermatitis (AD) management and how Incyte is utilizing its expertise in immunology to address unmet needs for patients.What to do if your practice’s social accounts are inactive
https://practicaldermatology.com/topics/practice-management/what-to-do-if-your-practices-social-accounts-are-inactive/20127/Social media is the can’t miss marketing platform of 2022. However, it has been around long enough that many businesses have already tried it and given up years ago. If you are among the many dermatology practices with an old, outdated, nearly inactive Facebook or other social accounts, check out thRacism in Medicine and the Problem of Health Care Disparities
https://practicaldermatology.com/topics/skin-of-color/racism-in-medicine-and-the-problem-of-health-care-disparities/23761/Dermatologists can work to improve health outcomes for all patients.Scientifically Speaking: Effective By Design with Josh Makower, MD
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-effective-by-design-with-josh-makower-md/20106/Josh Makower, MD has been at the forefront of several medical innovations. Listen in as he describes his approach and discusses his latest product with host Joel L. Cohen, MD. The Avéli device from Revelle Aesthetics is FDA-cleared to reduce cellulite in the buttocks and thighs temporarily.DermWireTV: Dupixent for Kids; Epsolay Launch; Scleroderma Awareness; Chicago Derms Celebrate Diversity
https://practicaldermatology.com/topics/practice-management/dermwiretv-dupixent-for-kids-epsolay-launch-scleroderma-awareness-chicago-derms-celebrate-diversity/20100/Epsolay (benzoyl peroxide 5%) Cream from Galderma is now available for the topical treatment of rosacea. It was developed by Sol-Gel. Dupixent from Sanofi and Regeneron is now the only biologic medicine FDA approved for use from infancy through adulthood for the management of atopic dermatitis. JuneDermWireTV: Epsolay Approval; See My Skin from Vaseline; Jori Launch; Novartis Grant for Farmworker Justice
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-epsolay-approval-see-my-skin-from-vaseline-jori-launch-novartis-grant-for-farmworker-justice/20094/Vaseline’s new See My Skin Campaign aims to help consumers of all skin types recognize skin diseases and connect them with dermatologists who can help manage them. Uchenna Okereke, MD discusses the initiative. Farmworker Justice, an organization dedicated to empowering farmworkers to improve immigraContact Derm and AD Updates
https://practicaldermatology.com/conferences/maui-derm-2022/contact-derm-and-ad-updates/20052/Matthew Zirwas, MD reviews allergens that have made the list of Allergen of the Year over the program's 20-year history and what dermatologists should know about these allergens. He also provides an overview of his approach to diagnosing and treating atopic dermatitis.DermWireTV: SPF Accuracy, Dupixent PN Data, AD Pipeline
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-spf-accuracy-dupixent-pn-data-ad-pipeline/20009/Researchers from the Environmental Working Group say that many sunscreens offer less than half their stated SPF protection against UVB. The Thriving in Aesthetics educational series featuring Sabrina Fabi, MD and Steven Dayan, MD is returning with a focus on diversity in aesthetics. As eczema awareDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global P